Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Anaptysbio Inc Is A Clinical-Stage Biotechnology Company. The Company Is Focused On Developing Antibody Product Candidates For Unmet Medical Needs In Inflammation And Immuno-Oncology. The Company Is Developing Immune Cell Modulating Antibodies, Including Two Wholly Owned Checkpoint Agonists In Clinical-Stage Development, For Autoimmune And Inflammatory Diseases; Rosnilimab, Pd-1 Agonist In A Phase 2b Trial For The Treatment Of Moderate-To-Severe Rheumatoid Arthritis (Ra) And A Phase 2 Trial For The Treatment Of Moderate-To-Severe Ulcerative Colitis (Uc); And Anb032, Btla Agonist, In A Phase 2b Trial For The Treatment Of Moderate-To-Severe Atopic Dermatitis (Ad).